Rhythm Biosciences Secures Contract for Breast Cancer Risk Study with University of Melbourne

Rhythm Biosciences Ltd. ( (AU:RHY) ) has issued an announcement.

Rhythm Biosciences Ltd has announced a 12-month contract through its subsidiary Genetype with the University of Melbourne to provide geneType™ Breast Cancer Risk assessment. This partnership aims to enhance breast cancer screening for Australian women aged 40-59 by integrating personalized risk assessment approaches, which align with national guidelines. The study will incorporate factors like family history, mammographic breast density, and polygenic risk scores, potentially setting a new standard for risk-stratified screening. This collaboration not only accelerates Genetype’s commercial growth but also strengthens its market position in predictive cancer diagnostics, offering significant implications for stakeholders by potentially improving the effectiveness of breast cancer screening and expanding the use of personalized risk models.

More about Rhythm Biosciences Ltd.

Rhythm Biosciences Ltd (ASX: RHY) is an Australian medical diagnostics company focused on developing simple, affordable blood tests for early cancer detection. Founded in 2017 and headquartered in Melbourne, the company aims to improve patient outcomes and reduce the global burden of cancer by working with global partners for the commercialization and distribution of its solutions. Its products include the ColoSTAT® Test-Kit for colorectal cancer detection and the geneType™ platform for comprehensive genetic risk assessments across multiple diseases.

Average Trading Volume: 250,467

Technical Sentiment Signal: Strong Sell

Current Market Cap: A$18.26M

For a thorough assessment of RHY stock, go to TipRanks’ Stock Analysis page.